NCT Number: NCT00223574
Canadian Trial of Dietary Carbohydrates in Diabetes
A long-term low carbohydrate, high monounsaturated fat diet, compared to a high carbohydrate, low glycemic index diet, results in more rapid progression of diabetes; i.e. increased fasting glucose and glycated hemoglobin, reduced beta-cell function and insulin sensitivity and increased free fatty acids. The deleterious effects of a high carbohydrate diet on plasma lipids are only temporary and do not persist beyond 6 months. A long-term high carbohydrate, low glycemic index diet, compared to a high carbohydrate, high glycemic index diet, improves glycemic control and beta-cell function
Looking for future studies?
Notify MeKey information
Conditions
Age range
35 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Clinical Trials Centre, Edmonton, Alberta, Canada
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- male or non-pregnant/non-lactating females with type 2 diabetes treated by diet alone
- age 53-75y
- body mass index 25-40kg/m^2 (Caucasian) or 23-40kg/m^2 (other)
- HbA1c <=130% of upper limit of normal of local hospital lab
Exclusion criteria
- use of any hypoglycemic or anti-hyperglycemic drug within 6 months of randomization
- major cardiovascular event or major surgery within 6 months of randomization
- serum triglycerides >10mmol/L
- presence of other major debilitating disorder such as liver disease, renal failure or cancer
- presence of gastrointestinal disorder or use of drug which is likely to alter gastrointestinal motility or nutrient absorption
- use of oral steroids
- substance or alcohol abuse
- simultaneous participation in another clinical trial
- allergy or intolerance to more than one of wheat, barley, corn, oats, potato, legumes, nuts, psyllium, olives, avocado or canola
- unwilling or unable to follow the protocol and/or give informed consent
- subjects planning to be on holiday for more than 8 weeks in a row or a total of 12 weeks in the year in locations to which they will not take study food
Treatment and study plan
high carbohydrate, low glycemic index foods
Druglow carbohydrate, high monounsaturate fat foods
DrugPrimary outcomes
-
glycated hemoglobin
Secondary outcomes
-
Body weight
-
waist circumference
-
occurrence of diet failure
-
fasting glucose
-
fasting C-reactive protein
-
fasting lipids (total, HDL and LDL cholesterol and triglcyerides)
-
fasting apolipoproteins A1 and B100
-
fasting free fatty acids
-
fasting short chain fatty acids
-
plasma glucose and insulin 30, 60 and 120min after 75g oral glucose
-
insulin sensitivity (HOMA)
-
beta-cell function (30min-fasting insulin)/(30min-fasting glucose)
-
metabolic profile (glucose, insulin, triglycerides and FFA during 8h profile)
-
quality of life
-
gastrointestinal symptoms
-
diet satisfactio
Sponsors and collaborators
Lead sponsor
University of Toronto
Other
Registry information
Official study title
Long-Term Effect of Altering the Source or Amount of Dietary Carbohydrate in Type 2 Diabetes
Important dates
- Study start
- 2002
- Study completion
- 2004
- First posted
- Sep 22, 2005
- Registry last updated
- Sep 22, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
NCT05929079
Apnea, Body Weight
Anniston, Alabama, United States
View Trial DetailsA Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
NCT06649344
Diabetes Mellitus, Diabetes Mellitus, Type 2
Tianjin, Tianjin Municipality, China
View Trial DetailsEfficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial
NCT07732218
Diabetes Mellitus, Diabetes Mellitus, Type 2
Peshawar, Khyber Pakhtunkhwa, Pakistan
View Trial DetailsmHealth Intervention to Increase Physical Activity in Prediabetes and Type 2 Diabetes
NCT05351359
Diabetes Mellitus, Diabetes Mellitus, Type 2
Prague, Czechia
View Trial Details